3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Magnetic Resonance Spectroscopy
12
gallium Ga 68 dotatate
6
Everolimus
6
lutetium Lu 177 dotatate
5
Radiosurgery
5
Proton Therapy
5
Bevacizumab
5
pembrolizumab
4
Surveys and Questionnaires
4
Specimen Handling
4
Hydroxyurea
4
abemaciclib
3
Tranexamic Acid
3
Surgical Procedures, Operative
3
Sodium Chloride
3
Ga(III)-DOTATOC
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
vistusertib
2
trametinib
2
ribociclib
2
arginyllysine
2
aldesleukin
2
Yoga
2
Whole Body Imaging
2
Sunitinib
2
Saline Solution
2
Ropivacaine
2
Radiotherapy
2
Protons
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Meningioma
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled